EMCURENSEEmcure Pharmaceuticals LimitedMediumNeutral
Announced Fri, 8 May · 13:16 IST

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ESG Rating

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.1%1-day move
₹1656.70
prior close
₹1660.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0+0.1+0.2+0.2+1.1+0.0-0.1+0.9+3.0+3.3+3.0+3.8+9.3
Up moveDown movePending
AI summary

Emcure Pharmaceuticals has received a voluntary ESG (Environmental, Social, and Governance) rating of 21 from NSE Sustainability Ratings & Analytics Limited, a SEBI-registered ESG rating provider. The rating is for Financial Year 2024-25 and was assigned based on publicly available information. The company disclosed this information to NSE and BSE on May 8, 2026, after receiving notification via email on May 7, 2026. This filing is made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The rating was independently assigned on a voluntary basis, indicating the company's willingness to be transparent about its sustainability and governance practices.

Likely market impact

The voluntary ESG rating demonstrates Emcure's commitment to transparency and sustainability disclosure, which may positively influence ESG-focused institutional investors and enhance the company's reputation among socially conscious stakeholders.